Clinical evidence demonstrates that early insulin therapy (2–5 weeks) in individuals newly diagnosed with type 2 diabetes can yield years of glycaemic control [67–70], supporting the reversibility of early beta cell dysfunction. Here, INS is linked to type 2 diabetes mellitus.